arch43

EN_01454483_0448

30,00 EUR Private use
Making print for private purpose, storage in computer memory, no distribution rights.
40,00 EUR Internet - private use
Strictly for editorial, single use on a personal (nonprofit) web site, Internet portal, social media (Facebook, Instagram etc.), blog for 1 year. Not for resale. Maximum picture size 2000px.
75,00 EUR Internet commercial use
Strictly for editorial, single use on a commercial web site, Internet portal, social media (Facebook, Instagram etc.), blog for 1 year. Not for resale. Maximum picture size 2000px.
90,00 EUR Print use
Strictly for editorial, single use, inside of newspaper, magazine, book (including digital version), one edition, one single country. Not for resale.

Gross prices

special instructions

SEE CAPTION FOR MORE INFORMATION / RESTRICTED TO EDITORIAL USE - MANDATORY CREDIT "AFP PHOTO / UNIVERSITY OF OXFORD / John Cairns " - NO MARKETING - NO ADVERTISING CAMPAIGNS - RESTRICTED TO ILLUSTRATING STORIES RELATED TO THE PARTICULAR VACCINE, EVENTS AN

caption

TOPSHOT - An undated handout picture released by the University of Oxford on November 23, 2020 shows a vial of the University's COVID-19 candidate vaccine, known as AZD1222, co-invented by the University of Oxford and Vaccitech. - Scientists behind a coronavirus jab being developed in Britain on Monday hailed it as a potential "vaccine for the world", which could be cheaper to make and easier to store and distribute than its main rivals. The University of Oxford and its pharmaceutical partner AtraZeneca, said they were seeking regulatory approval for the vaccine after it showed an average 70-percent effectiveness. (Photo by John Cairns / University of Oxford / AFP) / RESTRICTED TO EDITORIAL USE - MANDATORY CREDIT "AFP PHOTO / UNIVERSITY OF OXFORD / John Cairns " - NO MARKETING - NO ADVERTISING CAMPAIGNS - RESTRICTED TO ILLUSTRATING STORIES RELATED TO THE PARTICULAR VACCINE, EVENTS AND FACTS MENTIONED IN THE CAPTION - DISTRIBUTED AS A SERVICE TO CLIENTS /

headline arch43

created date 2020-11-23

credit JOHN CAIRNS/AFP/East News

source AFP

byline JOHN CAIRNS

original transmission reference AFP_8VQ6AM

weight 2,29MB

size 34cm x 23cm by 300dpi

keywords - Show

2020, 23, 70-PERCENT, A, ADVERTISING, AFTER, AN, AND, APPROVAL, AS, ATRAZENECA, AVERAGE, AZD1222, BE, BEHIND, BEING, BRITAIN, BY, CAIRNS, CAMPAIGNS, CANDIDATE, CAPTION, CHEAPER, CLIENTS, CO-INVENTED, CORONAVIRUS, COULD, COVID-19, CREDIT, DEVELOPED, DISTRIBUTE, DISTRIBUTED, EASIER, EDITORIAL, EFFECTIVENESS, EVENTS, FACTS, FOR, HAILED, HANDOUT, HEALTH, HORIZONTAL, ILLUSTRATING, IN, IT, ITS, JAB, JOHN, KNOWN, MAIN, MAKE, MANDATORY, MARKETING, MENTIONED, MONDAY, NO, NOVEMBER, OF, ON, OXFORD, PANDEMIC, PARTICULAR, PARTNER, PHARMACEUTICAL, PICTURE, POTENTIAL, REGULATORY, RELATED, RELEASED, RESEARCH, RESTRICTED, RIVALS, SAID, SCIENTISTS, SEEKING, SERVICE, SHOWED, SHOWS, STORE, STORIES, STR, THAN, THE, THEY, TO, TOPSHOT, TOPSHOTS, UNDATED, UNIVERSITY, USE, VACCINE, VACCINES, VACCITECH, VIAL, WERE, WHICH, WORLD,